Free tool
FAERS Monitor: Myalept
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 125390 or its brand name (Myalept, Metreleptin). Reports on generic versions are filed under their own applications.
Reports
1,263
Serious
654
52% of reports
Hospitalization
374
Death reported
71
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- product dose omission issue102
- weight decreased93
- therapy cessation92
- blood glucose increased84
- drug ineffective77
- off label use68
- therapy interrupted66
- nausea61
- blood triglycerides increased54
- treatment noncompliance53
- weight increased52
- injection site pain48
- maternal exposure during pregnancy48
- decreased appetite47
- glycosylated haemoglobin increased41
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 15 |
| 2015 | 51 |
| 2016 | 95 |
| 2017 | 87 |
| 2018 | 89 |
| 2019 | 140 |
| 2020 | 203 |
| 2021 | 74 |
| 2022 | 93 |
| 2023 | 111 |
| 2024 | 134 |
| 2025 | 70 |
| 2026 | 101 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,896 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blood triglycerides increasedSignal | 54 | 51.1 | 39.3 | 2,595 |
| therapy cessationSignal | 92 | 29.9 | 24.6 | 2,543 |
| glycosylated haemoglobin increasedSignal | 41 | 27.1 | 20.0 | 1,004 |
| treatment noncomplianceSignal | 53 | 16.1 | 12.4 | 739 |
| therapy interruptedSignal | 66 | 15.4 | 12.2 | 876 |
| maternal exposure during pregnancySignal | 48 | 9.0 | 6.8 | 333 |
| blood glucose increasedSignal | 84 | 7.4 | 6.0 | 465 |
| product dose omission issueSignal | 102 | 5.8 | 4.8 | 404 |
| weight decreasedSignal | 93 | 5.5 | 4.6 | 347 |
| weight increasedSignal | 52 | 3.9 | 3.0 | 109 |
| decreased appetiteSignal | 47 | 3.4 | 2.5 | 77 |
| injection site painSignal | 48 | 2.6 | 2.0 | 47 |
| off label use | 68 | 1.3 | 1.0 | 4 |
| nausea | 61 | 1.3 | 1.0 | 4 |
| drug ineffective | 77 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.